Cargando…

The utility of cMet as a diagnostic tissue biomarker in primary colorectal cancer

The transmembrane protein, cMet, is thought to be overexpressed and activated in colorectal cancer (CRC). This study explored its potential as a diagnostic tissue biomarker for CRC in a large human CRC tissue collection obtained from a randomized clinical trial. Tissue microarrays of matched normal...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, Gemma R., Khot, Mohammed Ibrahim, Tiernan, Jim P., West, Nick P., Perry, Sarah L., Maisey, Tom I., Hughes, Thomas A., Jayne, David G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139376/
https://www.ncbi.nlm.nih.gov/pubmed/33951261
http://dx.doi.org/10.1111/iep.12395
_version_ 1783695995186446336
author Armstrong, Gemma R.
Khot, Mohammed Ibrahim
Tiernan, Jim P.
West, Nick P.
Perry, Sarah L.
Maisey, Tom I.
Hughes, Thomas A.
Jayne, David G.
author_facet Armstrong, Gemma R.
Khot, Mohammed Ibrahim
Tiernan, Jim P.
West, Nick P.
Perry, Sarah L.
Maisey, Tom I.
Hughes, Thomas A.
Jayne, David G.
author_sort Armstrong, Gemma R.
collection PubMed
description The transmembrane protein, cMet, is thought to be overexpressed and activated in colorectal cancer (CRC). This study explored its potential as a diagnostic tissue biomarker for CRC in a large human CRC tissue collection obtained from a randomized clinical trial. Tissue microarrays of matched normal colorectal epithelium and primary cancer were prepared from specimens obtained from 280 patients recruited to the MRC CLASICC trial (ISRCTN 74883561) and interrogated using immunohistochemistry for cMet expression. The distribution and intensity of immunopositivity was graded using a validated, semiquantifiable score, and differences in median scores analysed using the Wilcoxon signedrank test. A receiver operating characteristic (ROC) curve was plotted to measure the diagnostic accuracy of cMet as a biomarker in CRC. Epithelial cell membrane expression of cMet differed significantly between CRC and normal colorectal tissue: median 12.00 (Interquartile range (IQR) 615) versus median 6.00 (IQR 2.7012.00) respectively (P=<.0001). ROCAUC analysis of cMet expression yielded a CRC diagnostic probability of 0.66 (95% CI: 0.61 to 0.70; P<.0001). A score of 14.50 showed high specificity at 85.32% (95% CI 80.33%89.45%) but sensitivity of only 30.92% (CI 25.37%36.90%). Thus cMet is consistently overexpressed in human CRC as compared to normal colorectal epithelium tissue. cMet expression may have a role in diagnosis and prognostication if combined with other biomarkers.
format Online
Article
Text
id pubmed-8139376
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-81393762021-05-24 The utility of cMet as a diagnostic tissue biomarker in primary colorectal cancer Armstrong, Gemma R. Khot, Mohammed Ibrahim Tiernan, Jim P. West, Nick P. Perry, Sarah L. Maisey, Tom I. Hughes, Thomas A. Jayne, David G. Int J Exp Pathol Original Articles The transmembrane protein, cMet, is thought to be overexpressed and activated in colorectal cancer (CRC). This study explored its potential as a diagnostic tissue biomarker for CRC in a large human CRC tissue collection obtained from a randomized clinical trial. Tissue microarrays of matched normal colorectal epithelium and primary cancer were prepared from specimens obtained from 280 patients recruited to the MRC CLASICC trial (ISRCTN 74883561) and interrogated using immunohistochemistry for cMet expression. The distribution and intensity of immunopositivity was graded using a validated, semiquantifiable score, and differences in median scores analysed using the Wilcoxon signedrank test. A receiver operating characteristic (ROC) curve was plotted to measure the diagnostic accuracy of cMet as a biomarker in CRC. Epithelial cell membrane expression of cMet differed significantly between CRC and normal colorectal tissue: median 12.00 (Interquartile range (IQR) 615) versus median 6.00 (IQR 2.7012.00) respectively (P=<.0001). ROCAUC analysis of cMet expression yielded a CRC diagnostic probability of 0.66 (95% CI: 0.61 to 0.70; P<.0001). A score of 14.50 showed high specificity at 85.32% (95% CI 80.33%89.45%) but sensitivity of only 30.92% (CI 25.37%36.90%). Thus cMet is consistently overexpressed in human CRC as compared to normal colorectal epithelium tissue. cMet expression may have a role in diagnosis and prognostication if combined with other biomarkers. John Wiley and Sons Inc. 2021-05-05 2021-06 /pmc/articles/PMC8139376/ /pubmed/33951261 http://dx.doi.org/10.1111/iep.12395 Text en 2021 The Authors. International Journal of Experimental Pathology published by John Wiley & Sons Ltd on behalf of Company of the International Journal of Experimental Pathology (CIJEP). https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Armstrong, Gemma R.
Khot, Mohammed Ibrahim
Tiernan, Jim P.
West, Nick P.
Perry, Sarah L.
Maisey, Tom I.
Hughes, Thomas A.
Jayne, David G.
The utility of cMet as a diagnostic tissue biomarker in primary colorectal cancer
title The utility of cMet as a diagnostic tissue biomarker in primary colorectal cancer
title_full The utility of cMet as a diagnostic tissue biomarker in primary colorectal cancer
title_fullStr The utility of cMet as a diagnostic tissue biomarker in primary colorectal cancer
title_full_unstemmed The utility of cMet as a diagnostic tissue biomarker in primary colorectal cancer
title_short The utility of cMet as a diagnostic tissue biomarker in primary colorectal cancer
title_sort utility of cmet as a diagnostic tissue biomarker in primary colorectal cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139376/
https://www.ncbi.nlm.nih.gov/pubmed/33951261
http://dx.doi.org/10.1111/iep.12395
work_keys_str_mv AT armstronggemmar theutilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer
AT khotmohammedibrahim theutilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer
AT tiernanjimp theutilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer
AT westnickp theutilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer
AT perrysarahl theutilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer
AT maiseytomi theutilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer
AT hughesthomasa theutilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer
AT jaynedavidg theutilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer
AT armstronggemmar utilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer
AT khotmohammedibrahim utilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer
AT tiernanjimp utilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer
AT westnickp utilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer
AT perrysarahl utilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer
AT maiseytomi utilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer
AT hughesthomasa utilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer
AT jaynedavidg utilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer